Are the Pure In Situ Breast Ductal Carcinomas and Those Associated With Invasive Carcinoma the Same?

Abstract

It has been reported that pure ductal carcinoma in situ of the breast has morphologic differences from the in situ component of the invasive ductal carcinoma, as well estrogen and progesterone receptors expression according to their cytokeratin expression. However, there is no data comparing other tumor markers without using the cytokeratin expression. The objective of this study is to compare the expression of estrogen receptor (ER) and progesterone receptor (PR), HER-2/neu, p53, and Ki67 between pure ductal in situ carcinoma (pDCIS) and the in situ component of the invasive ductal carcinoma (DCIS + IDC) of the breast, and the in situ component to the invasive component of the same tumor (DCIS + IDC). The immunohistochemistry expression of the tumor markers was performed in 45 cases of pDCIS and DCIS + IDC, yielding a total of 90 cases. Statistical analysis was carried out using Fisher exact test, having a P < 0.05, and Kappa index (kappa) to assess intratumoral concordance. In DCIS + IDC, the in situ and invasive components did not show a significant difference and Kappa index (kappa) was high (0.7-1) for positive and negative expression. ER and PR were significantly different between the pDCIS and DCIS + IDC (ER: 86.7 vs. 66.7% P = 0.04; PR: 80% vs. 55.6% P = 0.02). These findings suggest that in situ component of DCIS + IDC and pDCIS are distinct conditions.

Correlations of Hormone Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal Carcinoma Among Yemeni Women

“…The similarities between the expressions of these tumor markers suggest that these tumors belong to the same cellular clone in different phases of their growth, and the in situ components may represent cells with a higher potential of malignancy. These findings are in agreement to those reported by Schuetz et al, [19] where they identified the similarities between the gene expression of the in situ and invasive components of the same tumor by using microarray hierarchical cluster analysis, and with others [20,21].…”

“…Tumor markers: Tumor markers are molecules occurring in tissue that are associated with cancer and whose identification is useful in patient diagnosis and treatment or clinical management [17]. In this study, we compared the immunohistochemical expression of tumor markers (ER, PR, HER-2/neu, P53) between breast ductal carcinoma (IDC+NIDC), without sub typing into low and high grade, as it was carried out by Mario et al, [18] versus benign breast lesions. Moreover, we compared the immunohistochemistry expression of these markers within the different breast tumors (ie, IDC, NIDC), as well as, with clinicopathological features of these lesions.…”

Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis

“…The concordant expression of immunohistochemical 11 – 14 and genomic 15 – 17 markers supports the clonal relationship between breast DCIS and IDC-DCIS. However, survival in patients with DCIS in breast IDC remains uncertain.…”

A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy

“…Several studies have shown no differences in the biomarker expression in the DCIS component of IBCA versus IBCA only [17, 35]. We did not include basal markers for further characterization of the triple negative tumors.…”